STAQ Pharma, Inc., Denver, CO
Is STAQ Pharma, Inc. an FDA-registered 503B outsourcing facility?
Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names STAQ Pharma, Inc. in Denver, CO, first registered Feb 5, 2019 and most recently registered Dec 18, 2025. FDA lists its last inspection as Sep 8, 2026, with a Form FDA 483 issued; FDA lists the action on that inspection as “Open”.
FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.
- Location on FDA’s list
- Denver, CO
- Initial registration
- Feb 5, 2019
- Most recent registration
- Dec 18, 2025
- Last inspection
- Sep 8, 2026
- Form 483 issued at last inspection
- Yes
- Recall after last inspection
- No
- Action on last inspection
- Open
- Intends to compound sterile drugs from bulk substances
- Yes
- Earlier inspections
- FDA notes that an earlier inspection led to a Form 483, warning letter or other action
FDA inspections and actions on record
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this facility as STAQ Pharma, Inc., Denver, CO, a 503B facility, with 5 listed actions, including 2 Form 483s (2020 to 2025).
| Document | |||
|---|---|---|---|
| Jun 6, 2025 | FMD-145 letter | FMD-145 Letter Issued 06/06/2025 | Not linked by FDA |
| Mar 25, 2022 | FMD-145 letter | FMD-145 Letter Issued 03/25/2022 | Not linked by FDA |
| Sep 29, 2021 | Form 483 | 483 Issued 09/29/2021 | FDA copy (archived) |
| May 25, 2021 | FMD-145 letter | FMD-145 Letter Issued 05/25/2021 | Not linked by FDA |
| Sep 3, 2020 | Form 483 | 483 Issued 09/03/2020 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
Matched to the 503B list by city, state and the exact legal name with the same legal ending. Check the heading above against the facility you are looking for.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists STAQ Pharma, Inc., Denver, CO (FEI number 3015144909), matched to this page by exact name, city and state. It lists 3 inspections: 3 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Feb 10, 2025 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3015144909 | 1262991 |
| Sep 29, 2021 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3015144909 | 1155181 |
| Sep 3, 2020 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3015144909 | 1128435 |
Form 483s FDA has published for this site
- Sep 29, 2021: Form 483 to STAQ Pharma, Inc., published May 26, 2022. fda.gov
- Sep 3, 2020: Form 483 to STAQ Pharma, Inc., published Nov 2, 2020. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 5 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Aug 25, 2020 to Sep 3, 2020: 5 observations
- Firm on the cover
- STAQ Pharma, Inc., 14135 E 42nd Ave Ste 50, Denver, CO 80239-5214
- FEI number
- 3015144909
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 6th & Kipling St. (P. 0. Box 25087) Denver, CO 80225-0087
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up.
For example:
a) An investigation (DEV 20-020, July 2020) concerning the leaking of finished and filled syringes in Ketamine HCL 10 mg/ml, 5 ml in a 5 ml syringe lot <Redacted B4> discovered during visual inspection of filled drug product, did not fully pursue root cause to determine adequacy of container and closure system integrity for marketed sterile drug products and specifically why filled syringes were found leaking. Per the investigation, "The most probable root cause for product leaking beyond the plunger stoppers in <Redacted B4> syringes for lot <Redacted B4> is materials [the syringe]." ... " [STAQ] Method and machine1y are possible contiibuting factors ... " ...
Observation 2
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.
For example:
a) The Smoke Study performed in Production Room D is not adequate to show production areas have unidirectional airflow, as the Study shows detection of some instances where there is turbulence.
I) The Smoke Study in the ISO 5 hood in Room D shows that air (smoke) rises towards the ceiling in areas adjacent to the ISO 5 Hood instead of cascading towards the floor where uptakes are located, indicating turbulence instead of unidirectional airflow. Turbulence is also indicated in areas where ISO 5 air meets ISO 7 air.
II) The ISO 7 area, where the ISO 5 hood is located, was not folly included in the Smoke Study to demonstrate air flow adequacy and impact on the ISO 5 environment. The hood generates <Redacted B4> directed (ISO 5) air and is open to the ISO 7 environment. which produces vertically (downward) flowing air.
The Smoke Study video shows the following from the hood in Production Room D:
i) At 00:37-00:40 there is turbulence
ii) At 00:50-00:54 there is turbulence ...
Observation 3
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
For example:
a) Media plates used for detecting microbes (in ISO 5 hood areas during filling) with active air sampling do not contain neutralizing agents to ensure detection and growth of microbes in the presence of disinfecting agents utilized in the filling room.
b) There is no environmental monitoring of aseptic setup in ISO 5 hood areas, i.,e., no viable (air and personnel) and no paiticle monitoring.
Observation 4
Aseptic processing areas are deficient regarding the system for cleaning an ddisinfecting the room and equipment to produce aseptic conditions.
Specifically, classified area disinfecting procedures (SOP 201 Classified Area Cleaning) do not ensure contact times are accomplished, there is no contact time established for <Redacted B4> and there is nothing in the procedure determining how much area can be wiped with a single mop surface or hand wipe surface. For example, it was observed on 8/27/2020, as a regular practice, that the Operator used the same hand wipe surface to disinfect multiple production surfaces within the same ISO area.
Observation 5
The labels of your outsourcing facility's drug products are deficient.
The templated labels received of your outsourcing facility's drug products does not include information required by section 503B(a)(l0)(A) and 503B(a)(l0)(B) . Specifically, the dosage form of the product, such as "Injection" for the IV formulations, was missing. Some examples include:
Fentanyl Citrate 100 mcg/2ml
Fentanyl Citrate 250 mcg/5ml
Fentanyl Citrate 1000 mcg/20ml
Hydromorphone HCL 0.4mg/2ml
Hydromorphone HCL 2mg/10ml
Ketamine HCL 50mg/5ml
Ketamine HCL 30mg/3ml
Midazolam 2mg/2ml
Midazolam 25mg/25ml
Morphine Sulfate 2mg/2ml
Morphine Sulfate 5mg/5ml
Linked 483s whose text is not shown
- Sep 29, 2021: FDA document 158588: its numbered observations could not be read reliably from the PDF text.
GLP-1 records in this index
No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (STAQ Pharma, Inc.). That is not a finding beyond this index’s search.
The STAQ Pharma, Inc. pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.